SCHEMBL24724937

SCHEMBL24724937

CC(C)CN1CCC(c2ccc(C(=O)C(C)C)nc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.47
KDM4E B2RXH2 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GLA P06280 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
HIF1A Q16665 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CSF1R P07333 1/20 0.42
FLT3 P36888 1/20 0.42
TLR9 Q9NR96 7/20 0.41
TLR8 Q9NR97 7/20 0.41
TLR7 Q9NYK1 7/20 0.41
KDM4A O75164 1/20 0.40
KDM4B O94953 1/20 0.40
KDM5C P41229 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
TACR3 P29371 1/20 0.39
SLC18A3 Q16572 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24933097 0.83 NAMPT (0.49) NAMPTTLR9TLR8TLR7SLC18A3
SCHEMBL25030606 0.79 SLC18A3 (0.40) KDM4ESMN1; SMN2GLAHTTKMT2A
SCHEMBL24724945 0.78 NAMPT (0.43) NAMPTKDM4ESMN1; SMN2KDM4AKDM4B
SCHEMBL24933096 0.77 PARP1 (0.43) KMT2ACYP2D6
SCHEMBL12367648 0.75 TACR3 (0.41) NAMPTKDM4ESMN1; SMN2TDP1TLR9
SCHEMBL27282972 0.72 KDM4E (0.59) NAMPTKDM4ESMN1; SMN2GLAHTT
SCHEMBL12367652 0.72 KDM4E (0.42) NAMPTKDM4ESMN1; SMN2TACR3CYP2D6
SCHEMBL24724942 0.70 ESRRG (0.45) SLC18A3
SCHEMBL23374690 0.70 SLC18A3 (0.49) NAMPTTLR9TLR8TLR7SLC18A3
SCHEMBL20038345 0.69 SLC18A3 (0.46) TLR9TLR8TLR7SLC18A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023009554-A1 METHODS TO REDUCE ADVERSE EFFECTS OF GENE OR BIOLOGICS THERAPY AVILAR THERAPEUTICS, INC. (US) 2023-02-02 WO disclosed
WO-2022235699-A2 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed